PD-Rx Pharmaceuticals, Inc. (PDRX)
OTCMKTS
· Delayed Price · Currency is USD
2.760
+0.010 (0.36%)
At close: Apr 16, 2025
PD-Rx Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 |
| Revenue | 18.95 | 21.27 | 28.72 | 21.6 | 21.03 | Upgrade
|
| Revenue Growth (YoY) | -10.93% | -25.92% | 32.93% | 2.74% | 0.74% | Upgrade
|
| Cost of Revenue | 13.32 | 14.56 | 17.65 | 14.65 | 14.77 | Upgrade
|
| Gross Profit | 5.62 | 6.71 | 11.06 | 6.96 | 6.26 | Upgrade
|
| Selling, General & Admin | 6.58 | 6.9 | 7.06 | 6.08 | 6.5 | Upgrade
|
| Operating Expenses | 6.58 | 6.9 | 7.06 | 6.08 | 6.5 | Upgrade
|
| Operating Income | -0.95 | -0.19 | 4 | 0.88 | -0.24 | Upgrade
|
| Interest & Investment Income | 0.23 | 0.06 | 0.02 | 0.01 | 0.04 | Upgrade
|
| EBT Excluding Unusual Items | -0.73 | -0.13 | 4.02 | 0.89 | -0.2 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.01 | 0 | 0.03 | 0.01 | - | Upgrade
|
| Other Unusual Items | - | - | - | 0.93 | - | Upgrade
|
| Pretax Income | -0.71 | -0.13 | 4.05 | 1.83 | -0.2 | Upgrade
|
| Income Tax Expense | 0.04 | -0.03 | 1.02 | -0.02 | 0.18 | Upgrade
|
| Net Income | -0.75 | -0.1 | 3.03 | 1.86 | -0.38 | Upgrade
|
| Net Income to Common | -0.75 | -0.1 | 3.03 | 1.86 | -0.38 | Upgrade
|
| Net Income Growth | - | - | 63.44% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 2 | 2 | 2 | 2 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 2 | 2 | 2 | 2 | 2 | Upgrade
|
| Shares Change (YoY) | 0.22% | -1.42% | -3.54% | -1.56% | 35.16% | Upgrade
|
| EPS (Basic) | -0.46 | -0.06 | 1.83 | 1.08 | -0.22 | Upgrade
|
| EPS (Diluted) | -0.46 | -0.06 | 1.83 | 1.08 | -0.22 | Upgrade
|
| EPS Growth | - | - | 69.44% | - | - | Upgrade
|
| Free Cash Flow | -1.43 | 1.36 | 2.69 | -0.57 | -0.64 | Upgrade
|
| Free Cash Flow Per Share | -0.87 | 0.83 | 1.62 | -0.33 | -0.36 | Upgrade
|
| Gross Margin | 29.68% | 31.56% | 38.52% | 32.20% | 29.77% | Upgrade
|
| Operating Margin | -5.03% | -0.90% | 13.94% | 4.06% | -1.13% | Upgrade
|
| Profit Margin | -3.98% | -0.46% | 10.57% | 8.59% | -1.83% | Upgrade
|
| Free Cash Flow Margin | -7.54% | 6.40% | 9.35% | -2.66% | -3.03% | Upgrade
|
| EBITDA | -0.8 | -0.05 | 4.13 | 0.99 | -0.08 | Upgrade
|
| EBITDA Margin | -4.22% | -0.24% | 14.39% | 4.59% | -0.36% | Upgrade
|
| D&A For EBITDA | 0.15 | 0.14 | 0.13 | 0.11 | 0.16 | Upgrade
|
| EBIT | -0.95 | -0.19 | 4 | 0.88 | -0.24 | Upgrade
|
| EBIT Margin | -5.03% | -0.90% | 13.94% | 4.06% | -1.13% | Upgrade
|
| Effective Tax Rate | - | - | 25.14% | - | - | Upgrade
|
| Advertising Expenses | 0.1 | 0.06 | 0.05 | 0.03 | 0.09 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.